Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue and is currently Chief Tecnology Officer for TissueTech and Chairman of the company’s Board of Directors. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the biological components of human placental tissues, to develop alternative products to deliver their natural therapeutic properties, and to expand their clinical applications. Dr. Tseng holds a medical degree from National Taiwan University and a Doctorate in Experimental Pathology from the University of California. He completed his residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins, and his fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding TissueTech, Dr. Tseng was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine.
Amy Tseng is TissueTech’s Chief Executive Office and a member of the company’s Board of Directors. Amy co-founded Bio-Tissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.
Prior to joining Ballast Point Ventures in 2004, Matt Rice began his career in the Health Care Investment Banking Group of Raymond James Financial, where he focused primarily on the specialty pharmaceutical, drug distribution and contract research organization sectors. Matt also worked in the Strategic Alliances group at the Novartis Institutes for BioMedical Research prior to rejoining Ballast Point Ventures as a Vice President in 2008.
In addition to serving on the Board of Directors of TissueTech, Matt currently serves on the Board of Directors at MolecularMD, Y-Prime, MeYou Health, Theragen, Iconixx, IRIS, and previously represented BPV at Innocutis. Matt leads Ballast Point Venture’s health care practice and also serves on the St. Joseph’s Hospitals Board of Directors (Baycare Health System). Matt holds a Bachelor’s Degree in Commerce from the University of Virginia and a Master of Business Administration from the Harvard Graduate School of Business Administration.
Bob White brings nearly 30 years of experience leading early stage companies and Fortune 500 business units within the medical technology sector.
He most recently served as President and CEO of Entellus Medical, Inc, which was acquired by Stryker in 2018, and previously was the President and Chief Executive Officer of TYRX, Inc, which was acquired by Medtronic in 2014. Prior to joining TYRX, Mr. White held several leadership positions in commercial operations, business development, international sales and marketing, operations and general management for Medtronic, Instromedix/Life Watch, Eli Lilly, IVAC/Alaris Medical, and General Electric.
Mr. White joined EW Healthcare in May 2019 as Operating Partner. He currently serves as a Director on the Board of AtriCure and Cardiva Medical.
Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
Shaunak Parikh is a Partner at EW Healthcare, a private equity firm specializing in growth stage investments across healthcare. With more than 10 years’ experience, Mr. Parikh focuses on investing in pharmaceuticals, medical devices, diagnostic and technology-enabled service opportunities. He also plays an active role in the management and value creation process of existing portfolio companies.
Prior to joining EW in 2013, Mr. Parikh was an Associate at Health Evolution Partners, a private equity firm focused on healthcare services, life sciences and HCIT. Previously, he worked in the investment banking group at Citigroup, where he focused on mergers and acquisitions primarily in the medical device and pharmaceutical sectors.
In addition to TissueTech, Mr. Parikh also serves as a Director on the Board of Encore Dermatology and as an observer for Cardiva Medical and Prolacta Biosciences.
Mr. Parikh earned his M.B.A. from The Wharton School at the University of Pennsylvania and graduated Phi Beta Kappa and with Honors from U.C.L.A with a B.S. in Microbiology, Immunology and Molecular Genetics and a B.A. in Economics.
John Arnott was most recently Operating Partner and Executive Chairman of multiple portfolio companies for The Riverside Company, one of the largest and oldest global private equity firms. Mr. Arnott’s career in healthcare dates back four decades. He has an extensive background in corporate, private equity, international, regional, and country operating environments, including senior positions with Idex Corporation, Alpine Biomed, Sierra Scientific, and Abbott Laboratories.
John’s career launched in 1977 when he began work for the National Health Service in the United Kingdom, ultimately serving as Chief Medical Laboratory Scientific Officer for the Welsh National Blood Transfusion Service. From 1990 to 2003, he held several executive positions at Abbott Laboratories, including Vice President and Regional Director of European Operations and corporate Vice President of the Hospital Products Division. Before joining Riverside, he served as Chief Executive Officer & Chairman of Alpine Biomed, Executive Chairman of Sierra Scientific and President of Idex Health & Science LLC.